Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inseal Medical Ltd.

www.insealmedical.com

Latest From Rinat Neuroscience Corp.

Antibody Approach To CGRP Offers Safer Mode For Migraine Prevention, Labrys Says

Labrys is ready to advance a monoclonal antibody to Phase II for prevention of chronic migraine, after releasing pooled safety from five Phase I trials conducted by Pfizer.

BioPharmaceutical United States

SV and Polaris Back Gerngross' New Antibody Play

Adimab is the latest venture in the resurgent large-molecule platform space. The company is founded by yeast platform pioneers Tillman Gerngross (Glycofi, Dartmouth) and Dane Wittrup (BioDisplay, MIT). The company's Series A pulled in $6.2 million from lead backers SV Life Sciences and Polaris Venture Partners.
BioPharmaceutical Strategy

A Look Back at 2006: The Pipeline Challenge

Our review of top stories of 2006 touches on a variety of subjects, but the majority drive to one über-theme: the pipeline challenge. Products suddenly disappeared into the generic abyss, with nothing new to take their places. Compounds likely to succeed didn't. The price of in-licensable products soared. Even relatively good news for pipelines largely reflected the absence of further bad news: the safety squabbles did not result in higher hurdles to product approvals.
BioPharmaceutical Strategy

Molecular Origami: Start-Ups Tackle Protein Folding

Start-ups are developing novel therapeutics that work by shepherding faulty proteins into their normal conformations. The risky approach, if successful, could dramatically increase the pharmaceutical arsenal. Drug companies remain skeptical, prefering to wait for clinical validation of the existing compounds before inking big deals.
BioPharmaceutical
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Inseal Medical Ltd.
  • Senior Management
  • Avi Penner, PhD, CEO
    Lone Wolinsky, VP, Dev.
  • Contact Info
  • Inseal Medical Ltd.
    Phone: 72-222-1880
    P.O. Box 3172 Caesarea, 38900
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register